NCT00555256View on ClinicalTrials.gov

A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)

PHASE1CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

December 31, 2012

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

sunitinib and rapamycin (Drug will be held)

Any toxicity causing a total of 14 days delay of therapy will be considered dose limiting.

Trial Locations (1)

63110

Washington University School of medicine, St Louis

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Washington University School of Medicine

OTHER